← Back to Search

CAR T-cell Therapy

UCARTCS1A for Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Cellectis S.A.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This trial is testing a new cancer treatment to see if it is safe and effective for people with multiple myeloma who have relapsed or are refractory.

Eligible Conditions
  • Relapsed or Refractory Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety of UCARTCS1A
Secondary outcome measures
Duration of Response
Overall Survival
Progression Free Survival
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dose EscalationExperimental Treatment1 Intervention
Several tested doses of UCARTCS1A until the Maximum Tolerated Dose (MTD) is identified.

Find a Location

Who is running the clinical trial?

Cellectis S.A.Lead Sponsor
5 Previous Clinical Trials
186 Total Patients Enrolled

Media Library

UCARTCS1A (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04142619 — Phase 1
Multiple Myeloma Research Study Groups: Dose Escalation
Multiple Myeloma Clinical Trial 2023: UCARTCS1A Highlights & Side Effects. Trial Name: NCT04142619 — Phase 1
UCARTCS1A (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04142619 — Phase 1
~2 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top